FA
MRTX

Financial Advantage’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Financial Advantage’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-200
Closed -$6K – 137
2015
Q1 		$6K Buy
+200
New +$4.69K 0.01% 108

Other funds holding MRTX

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.6B AUM 113.36% 1-Year Est. Return
Broadfin Capital
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
QVT Financial
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Financial Advantage's MRTX Position: Q2 2015 in Review

Financial Advantage sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2015, closing a stake of 200 shares — an estimated $6K sold.

Financial Advantage first reported a position in MRTX in Q1 2015 and held it in 1 quarter. The position peaked at $6K in Q1 2015. 66 funds tracked by Wall St. Rank hold MRTX as of Q2 2015.

  • Financial Advantage reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2015 after selling out during the quarter.
  • Financial Advantage sold 200 Mirati Therapeutics, Inc. Common Stock shares in Q2 2015, an estimated $6K.
  • Financial Advantage first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2015 and held it in 1 quarter.
  • Financial Advantage's Mirati Therapeutics, Inc. Common Stock position peaked at $6K in Q1 2015.
  • 66 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2015.

Based on Financial Advantage's 13F filing for Q2 2015, filed 24 Jul 2015.